CNS Goal: Happier Endings, Smarter Starts, Better Trials
With big pharma's flight from central nervous system (CNS) drug discovery, one conclusion of a recent Tufts report seems surprising on first read: The CNS new product pipeline is among the richest in the research-based drug industry.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter